Show simple item record

dc.contributor.advisorTuncel, Ercan
dc.contributor.authorDuran, Cevdet
dc.date.accessioned2021-05-08T12:16:44Z
dc.date.available2021-05-08T12:16:44Z
dc.date.submitted2006
dc.date.issued2018-08-06
dc.identifier.urihttps://acikbilim.yok.gov.tr/handle/20.500.12812/701589
dc.description.abstractÖZETMAKS MUM DOZ ORAL H POGL SEM K AJANLARLA OPT MAL GL SEM KREGÜLASYON SAĞLANAMAYAN T P 2 D YABET K HASTALARDAREPAGL N D-GLARG N NSÜL N KOMB NASYONU, AKARBOZ-GLARG NNSÜL N KOMB NASYONU VE TEK BAŞINA GLARG N NSÜL NTEDAV LER N N GL SEM K PARAMETRELER ÜZER NE ETK S N NDEĞERLEND R LMESTip 2 diyabetik hastalarda hastalık süresi ilerledikçe diyet ve oralantidiyabetik (OAD) tedaviye rağmen kan glukoz regülasyonu sağlanamaz vesıklıkla insülin tedavisine ihtiyaç duyulur. Son yıllarda sadece insülin tedavisiyerine insülin ve OAD kombinasyonu önerilmektedir. Bu çalışmamızda insülinglargin (IG)'in tek başına, repaglinid veya akarboz ile kombinasyonlarınınglisemik parametreler üzerine etkisi araştırıldı.Maksimum doz OAD kullanımına rağmen açlık kan glukozu (AKG) 140 mg/dl,Hemoglobin A1C'si (A1C) %9'un üzerinde olan 20 hastaya IG ve repaglinid(gurup 1), 18 hastaya IG ve akarboz (gurup 2), 10 hastaya ise IGmonoterapisi (gurup 3) uygulandı.Üç aylık tedavi sonrası AKG'nda başlangıca göre gurup 1'de %35.29, gurup2'de %37.28, gurup 3'de %5.04 düşüş oldu. Gurup 1 ve 2'de bu düşüşbaşlangıca ve gurup 3'e göre anlamlıydı. Tokluk kan glukozu gurup 1'de%14.84, gurup 2'de %31.05 azalırken, gurup 3'de %7.79 arttı. Bu değişimsadece gurup 2'de başlangıca ve gurup 3'e göre anlamlıydı. HemoglobinA1C'de gurup 1'de %27.78, gurup 2'de %25.17, gurup 3'de %10.92 düşüşoldu. Tüm guruplarda A1C'de düşüş oranları başlangıca göre ve gurup 1 ve2'de gurup 3'e göre anlamlıydı. Tedaviyle sekiz ölçüm kan glukozu sonuçlarıgün ortalaması gurup 1 ve 2'de anlamlı olarak azalırken, gurup 3'de arttı. Budeğişim gurup 1 ve 2'de gurup 3'e göre anlamlıydı.iTedavi süresince gurup 1'de başlangıca ve gurup 3'e göre daha fazla kiloartışı oldu. Hipoglisemik atak sıklığı bütün guruplarda benzerdi.Sonuç olarak maksimum doz OAD'lerle glisemik regülasyon sağlanamayantip 2 diyabetik hastalarda repaglinid ve akarboz'un IG ile kombinasyonuglisemik parametreler üzerine benzer ve olumlu etki göstermektedir.Anahtar Kelimeler: Tip 2 diyabet, insülin glargin, repaglinid, akarboz,sekonder yanıtsızlıkii
dc.description.abstractSUMMARYTHE EVALUATION OF THE EFFECTS OF COMBINATIONS OFREPAGLINIDE- GLARGINE INSULIN, ACARBOSE-GLARGINE INSULINAND GLARGINE INSULIN ALONE ON GLYCEMIC PARAMETERS IN TYPE2 DIABETIC PATIENTS IN WHOM OPTIMAL GLYCEMIC REGULATIONWERE NOT ACHIEVED WITH MAXIMAL DOSES OF ORALHYPOGLYCEMIC AGENTSEventhough under strict dietary regimen and oral antidiabetic drug (OAD)therapy, blood glucose regulation may not be achived as the duration of thedisease prolonged in type 2 diabetes and frequently insulin prescriptionbecomes necessary. Nowadays combinations of insulin and OAD?s are oftenprescribed instead of insulin alone. In this study the effects of insulin glargine(IG) alone, and combination with repaglinide or acarbose on glycemicparameters were studied.Patients who had blood glucose levels over 140 mg/dl and A1C 9% besidesmaximum OAD therapy were included in the study. Patients were divided intothree groups, according to the therapeutic regimen applied. In group 1; IGand repaglinide were applied to 20 patients, in group 2; IG and acarbose to18 patiens and in group 3 IG alone to 10 patients.After 3 months of therapy in group 1; 35.29% decrease, in group 2; 37.28%and in group 3; 5.04% decrease were achived in fasting blood glucose levels.The decrease group 1 and 2 were statistically significant compared withbegining values and group 3. Postprandial blood glucose levels weredecreased in groups 1 and 2 as 14.84% and 31.05%, respectively. Whereasit was increased 7,79% in group 3. It was statistically significant only ingroup 2 compared to the begining values and to the values of group 3. Bloodhemoglobin A1C levels were decreased in all groups as follows; in group 1decline was 27.78%, in group 2; 25.17%, and in group 3; 10.92%. Theidecline in A1C were statistically significant in all groups compared with thebegining and groups 1 and 2 compared to group 3. At the end of the study; 8points home blood glucose monitoring mean values were statisticallydeclined in group 1 and 2, whereas it was increased in group 3. This declinewas statistically significant in group 1 and 2, compared with group 3.During study, more weight gain was detected in group 1 compared with thebeginning and the other groups. Hypoglycemia incidence was similar in all.As a result IG combination with repaglinide or acarbose has similary, positiveeffect on glycemic parameters in type 2 diabetics, who haven?t beenachieved acceptabl glycemic control besides maximum OAD therapyKeywords: Type 2 diabetes, insulin glargine, repaglinide, acarbose,secondary failureiien_US
dc.languageTurkish
dc.language.isotr
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.rightsAttribution 4.0 United Statestr_TR
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectEndokrinoloji ve Metabolizma Hastalıklarıtr_TR
dc.subjectEndocrinology and Metabolic Diseasesen_US
dc.titleMaksimum doz oral hipoglisemik ajanlarla optimal glisemik regülasyon sağlanamayan tip 2 diyabetik hastalarda repaglinid-glargin insülin kombinasyonu, akarboz-glargin insülin kombinasyonu ve tek başına glargin insülin tedavilerinin glisemik parametrel
dc.title.alternativeThe evaluation of the effects of combinations of repaglinide- glargine insulin, acarbose-glargine insulin and glargine insulin alone on glycemic parameters in type 2 diabetic patients in whom optimal glycemic regulation were not achieved with maxima
dc.typedoctoralThesis
dc.date.updated2018-08-06
dc.contributor.departmentİç Hastalıkları Ana Bilim Dalı
dc.identifier.yokid169559
dc.publisher.instituteTıp Fakültesi
dc.publisher.universityULUDAĞ ÜNİVERSİTESİ
dc.identifier.thesisid193347
dc.description.pages50
dc.publisher.disciplineEndokrinoloji ve Metabolizma Bilim Dalı


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/embargoedAccess
Except where otherwise noted, this item's license is described as info:eu-repo/semantics/embargoedAccess